文献速递临床试验与 GCP真实世界研究与卫生经济

系列:实用临床试验与真实世界证据:第4篇 知情同意

Series: Pragmatic trials and real world evidence: Paper 4. Informed consent.
PubMed 文献 · J Clin Epidemiol · 2017-05-11

GetReal联盟旨在将真实世界证据更早纳入药品生命周期,以助决策者比较新药风险与获益。本文分析实用临床试验传统知情同意模式在招募、结果外推性和选择偏倚方面的挑战,并讨论整合知情同意、定向知情同意、广播知情同意及免除知情同意四种替代模式。

要点

  • 传统知情同意模式可能降低实用临床试验可行性,导致招募困难、结果外推性降低和选择偏倚。
  • 文章讨论整合知情同意、定向知情同意、广播知情同意和免除知情同意四种替代模式。
  • 各替代模式基于对尊重人原则和患者道德义务的不同态度,其规范后果需被承认并依据实证主张评估。

核心结论

  • 修改知情同意要求的规范后果应至少被承认,并应依据实证主张的有效性加以评估。

研究设计与样本

  • 本文为GetReal联盟(创新药物计划)的政策与方法学分析文章,分析实用临床试验知情同意的挑战并讨论四种替代知情同意模式。

主要发现

  • 传统知情同意模式被认为对实用临床试验可行性构成实质障碍,可导致招募困难、结果外推性降低和选择偏倚。
  • 整合知情同意、定向知情同意、广播知情同意和免除知情同意四种替代模式旨在克服操作和方法学挑战,同时仍向患者提供做出知情决策所需的相关信息。
  • 每种知情同意模式依赖于对尊重人原则及告知患者义务的不同态度,并反映关于共同善是否要求患者承担道德义务的不同观点。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The GetReal consortium of the Innovative Medicines Initiative aims to develop strategies to incorporate real-world evidence earlier into the drug life cycle to better inform health care decision makers on the comparative risks and benefits of new drugs. Pragmatic trials are currently explored as a means to generate such evidence in routine care settings. The traditional informed consent model for randomized clinical trials has been argued to pose substantial hurdles to the practicability of pragmatic trials: it would lead to recruitment difficulties, reduced generalizability of the results, and selection bias. The present article analyzes these challenges and discusses four proposed alternative informed consent models: integrated consent, targeted consent, broadcast consent, and a waiver of consent. These alternative consent models each aim at overcoming operational and methodological challenges, while still providing patients all the relevant information they need to make informed decisions. Each consent model, however, relies on different attitudes toward the principle of respect for persons and the related duty to inform patients as well as represents different views on whether the common good demands moral duties from patients. Such normative consequences of modifying consent requirements should be at least acknowledged and ought to be assessed in light of the validity of empirical claims.

来源:J Clin Epidemiol,查看原文。版权归原作者所有。

引用

  1. Kalkman S, van Thiel GJMW, Zuidgeest MGP, et al. Series: Pragmatic trials and real world evidence: Paper 4. Informed consent. J Clin Epidemiol. 2017. PMID: 28502809. doi:10.1016/j.jclinepi.2017.03.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。